相似文献
1
Weight gain during acute treatment of an initial pulmonary exacerbation is associated with a longer interval to the next exacerbation in adults with cystic fibrosis.
ERJ Open Res. 2017 Aug 25;3(3). doi: 10.1183/23120541.00057-2017. eCollection 2017 Jul.
2
Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.
Cochrane Database Syst Rev. 2025 Jan 20;1(1):CD009730. doi: 10.1002/14651858.CD009730.pub3.
3
Cytomegalovirus-associated pulmonary exacerbation in patients with cystic fibrosis.
ERJ Open Res. 2018 Jan 10;4(1). doi: 10.1183/23120541.00111-2017. eCollection 2018 Jan.
4
Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
Contemp Clin Trials. 2013 Nov;36(2):460-9. doi: 10.1016/j.cct.2013.09.004. Epub 2013 Sep 19.
5
Antibiotic duration and changes in FEV are not associated with time until next exacerbation in adult cystic fibrosis: a single center study.
BMC Pulm Med. 2017 Nov 29;17(1):160. doi: 10.1186/s12890-017-0503-6.
6
The Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC) trial: Rationale and design of a multi-center, double-blind, placebo-controlled trial of high dose bolus administration of vitamin D3 during acute pulmonary exacerbation of cystic fibrosis.
Contemp Clin Trials Commun. 2017 Jun;6:39-45. doi: 10.1016/j.conctc.2017.02.010. Epub 2017 Mar 9.
7
Vitamin D for the Immune System in Cystic Fibrosis (DISC): a double-blind, multicenter, randomized, placebo-controlled clinical trial.
Am J Clin Nutr. 2019 Mar 1;109(3):544-553. doi: 10.1093/ajcn/nqy291.
8
Therapeutic drug monitoring in cystic fibrosis and associations with pulmonary exacerbations and lung function.
Respir Med. 2023 Jun;212:107237. doi: 10.1016/j.rmed.2023.107237. Epub 2023 Apr 6.
9
Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study.
Lancet Respir Med. 2016 Aug;4(8):636-645. doi: 10.1016/S2213-2600(16)30105-9. Epub 2016 Jun 10.
10
Antibiotic Therapy for Pulmonary Exacerbations in Cystic Fibrosis-A Single-Centre Prospective Observational Study.
Antibiotics (Basel). 2023 Apr 9;12(4):734. doi: 10.3390/antibiotics12040734.
本文引用的文献
1
Pseudomonas aeruginosa quorum sensing molecules correlate with clinical status in cystic fibrosis.
Eur Respir J. 2015 Oct;46(4):1046-54. doi: 10.1183/09031936.00225214. Epub 2015 May 28.
2
Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
Thorax. 2016 Mar;71(3):223-9. doi: 10.1136/thoraxjnl-2014-206750. Epub 2015 Apr 24.
3
European Cystic Fibrosis Society Standards of Care: Best Practice guidelines.
J Cyst Fibros. 2014 May;13 Suppl 1:S23-42. doi: 10.1016/j.jcf.2014.03.010.
4
Accelerating the rate of improvement in cystic fibrosis care: contributions and insights of the learning and leadership collaborative.
BMJ Qual Saf. 2014 Apr;23 Suppl 1:i23-i32. doi: 10.1136/bmjqs-2014-002804.
5
The Cystic Fibrosis Foundation Patient Registry as a tool for use in quality improvement.
BMJ Qual Saf. 2014 Apr;23 Suppl 1:i9-14. doi: 10.1136/bmjqs-2013-002378. Epub 2014 Jan 17.
6
Measures of body habitus are associated with lung function in adults with cystic fibrosis: a population-based study.
J Cyst Fibros. 2013 May;12(3):284-9. doi: 10.1016/j.jcf.2012.08.008. Epub 2012 Sep 5.
7
Are measures of body habitus associated with mortality in cystic fibrosis?
Chest. 2012 Sep;142(3):712-717. doi: 10.1378/chest.11-2124.
8
Nutritional management of cystic fibrosis.
JPEN J Parenter Enteral Nutr. 2012 Jan;36(1 Suppl):60S-7S. doi: 10.1177/0148607111420156.
9
Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis.
Pediatr Pulmonol. 2011 Apr;46(4):393-400. doi: 10.1002/ppul.21374. Epub 2010 Oct 21.
10
Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis.
Respir Med. 2009 Mar;103(3):407-13. doi: 10.1016/j.rmed.2008.09.024. Epub 2008 Nov 22.
Zotero 插件